[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polycythemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polycythemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,69,97,125,147,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100638454","phase-4-the-effect-of-lisinopril-on-polycythemia-100638454",false,"NCT07594535","The Effect Of Lisinopril On Polycythemia","Inclusion Criteria:\n\n* Hemoglobin in Men: \\>16.5 g\u002FdL (10.3 mmol\u002FL).\n* Hemoglobin in Women \\>16.0 g\u002FdL (10.0 mmol\u002FL).\n* BMI 18-40 kg\u002Fm2.\n\nExclusion Criteria:\n\n* Positive JAK2 gene linked to Polycythemia Vera.\n* Current smoker or previous heavy smoker (\\>15 pack years) who quit less than 12 months prior to enrollment.\n* Resting SpO₂ ≤ 94% on room air.\n* Current or recent (within the past 6 months) use of testosterone or androgen supplementation.\n* Any confounding respiratory or renal disease, including diagnosed or suspected sleep apnea, or stage 3 and up of chronic kidney disease.\n* Any confounding hematologic disease that may alter hemoglobin level.\n* Currently treated with ACE inhibitors.\n* Currently treated with potassium-sparing diuretics.\n* Currently on SGLT2 or use within 4 weeks prior to screening.\n* Baseline systolic blood pressure ≤90 mmHg.\n* Baseline systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg.\n* Occupational exposure associated with chronically elevated COHb (auto repair, etc.).\n* History of anaphylaxis or angioedema.\n* Pregnant or breastfeeding.","ALL","18 Years","80 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The purpose of this study is to evaluate the effect of the (angiotensin-converting enzyme) ACE inhibitor lisinopril on hemoglobin, hematocrit, and erythropoietin levels in patients with secondary polycythemia due to high-oxygen-affinity hemoglobin variants, oxygen-sensing pathway mutations, or other unexplained and potentially irreversible forms of erythrocytosis. This study aims to determine whether ACE inhibition can effectively reduce excessive erythrocytosis by modulating erythropoietin production.",[26],"Polycythemia","NOT_YET_RECRUITING","2026-05-13",{"date":30,"type":31},"2026-05-18","ACTUAL",{"date":33,"type":20},"2026-07-01",{"date":35,"type":20},"2029-07-01",{"name":37,"class":38},"Mayo Clinic","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":39},"100111972","molecular-biology-of-polycythemia-and-thrombocytosis-100111972","NCT00722527","Molecular Biology of Polycythemia and Thrombocytosis","Inclusion Criteria:\n\n1. Subjects with an elevated hemoglobin concentration (\\>18 in males and \\>16 in females)\n2. Subjects with an elevated platelet count (\\>450,000)\n\nExclusion Criteria:\n\n1. Subjects who have a known acquired cause of polycythemia and thrombocytosis\n2. Subjects with heart disease, left to right heart shunt or severe pulmonary disease",{"count":47,"type":20},200,"OBSERVATIONAL","Our study is designed to characterize the clinical picture and genetic pattern of Polycythemia and Thrombocytosis. The purpose of this project is to find a gene and its mutation that causes these disorders. When this is accomplished, new therapies to control and eventually cure the disorder can be designed.",[26,51],"Thrombocytosis",[53,26,54,55,56,57,51,58],"Primary Familial and Congenital Polycythemia","Molecular Biology","Genetics","Erythropoiesis","EPOR mutation","Hypoxia","RECRUITING","2026-03-05",{"date":62,"type":31},"2026-03-09",{"date":64,"type":4},"2006-07",{"date":66,"type":20},"2028-07",{"name":68,"class":38},"University of Utah",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":39},"100519060","phase-2-129xe-mri-cardiopulmonary-100519060","NCT06038630","129Xe MRI Cardiopulmonary","129Xe Gas Exchange MRI to Visualize Cardiopulmonary Function","Inclusion Criteria for Healthy Volunteers:\n\n(Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial)\n\n1. Outpatients of either gender, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol (Consent must be given before any study procedures are performed.)\n3. Subject has no diagnosed pulmonary conditions\n4. Subject has not smoked in the previous 5 years\n5. Smoking history, if any, is less than or equal to 5 pack-years\n6. No history of using other inhaled products more than 1\u002Fweek for \\> 1 year\n\nInclusion Criteria for Transfusion and Phlebotomy Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following:\n\n1. Patients who are scheduled to receive a red cell transfusion for anemia.\n2. Patients who are scheduled to undergo therapeutic phlebotomy to treat erythrocytosis or polycythemia\n3. Healthy volunteers undergoing voluntary whole blood donation (healthy volunteer inclusion criteria noted above)\n\nInclusion Criteria for Oxygen Administration Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following categories (ILD, Dyspnea, CTEPH, or Healthy):\n\n1. Interstitial Lung Disease or Dyspnea\n\n   * Physician diagnosis of Interstitial Lung Disease by a pulmonologist using established criteria or physician referral of patient with dyspnea\n\n   OR\n2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)\n\n   * Patients with a diagnosis of CTEPH, defined as mean PA pressure \\>20 mmHg with a pulmonary vascular resistance \\>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation\n   * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans\n\n   OR\n3. Healthy Volunteer (criteria noted above)\n\nInclusion Criteria for Acute or Chronic Pulmonary Embolism Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following categories (Acute or Chronic)\n\n1. Acute Pulmonary Embolism\n\n   * Patients presenting with acute PE 24-48hrs post-admission\n   * Willing to return after 3-6 months of anti-coagulation therapy\n\n   OR\n2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)\n\n   * Patients with a diagnosis of CTEPH, defined as mean PA pressure \\>20 mmHg with a pulmonary vascular resistance \\>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation\n   * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans\n\nExclusion Criteria for All subjects:\n\nSubjects presenting with any of the following will not be included in the trial:\n\n1. MRI is contraindicated based on responses to MRI screening questionnaire\n2. Subject is pregnant or lactating\n3. Resting O2 saturation \\\u003C90% with maximum supplemental O2 delivered by nasal canula\n4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI\n5. Subject has history of any known ventricular cardiac arrhythmia\n6. Subject has history of cardiac arrest within the last year\n7. Subject does not fit into 129Xe vest coil used for MRI\n8. Subject cannot hold his\u002Fher breath for 10 seconds\n9. Subject deemed unlikely to be able to comply with instructions during imaging\n10. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements",true,{"count":78,"type":20},125,[80],"PHASE2","The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.",[83,84,85,86,26,87],"Interstitial Lung Disease","Chronic Thromboembolic Pulmonary Hypertension","Acute Pulmonary Embolism","Anemia","Dyspnea","2026-02-02",{"date":90,"type":31},"2026-02-04",{"date":92,"type":31},"2024-01-12",{"date":94,"type":20},"2028-06-30",{"name":96,"class":38},"Bastiaan Driehuys",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":39},"100619163","potential-biological-and-physiological-determinants-for-exercice-in-patients-with-polycythemia-vera-100619163","NCT07341048","Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia Vera","Characterization of Exercise Intolerance in Patients With Polycythemia Vera: Study of Potential Biological and Physiological Determinants.","ACTIVAQ","Inclusion Criteria:\n\n* Patient aged at least 18 years and under 70.\n* Patient followed for a diagnosis of Polycytemia vera (confirmed JAK2 V617F mutation) and who were prescribed a CPET because of their wish to resume regular physical activity.\n* Patient affiliated with or benefiting from a social security scheme.\n\nExclusion Criteria:\n\n* Any known history of heart disease or chronic respiratory illness likely to affect VO₂max independently of Polycytemia vera (e.g., asthma), according to the investigator's judgment.\n* Any known history of major thromboembolic complication, according to the investigator's judgment.\n* Body mass index (BMI) greater than 35, according to the investigator's judgment.\n* Participation in another interventional research protocol that may interfere with the present study, according to the investigator's judgment.\n* Adult subject under legal protection measures (guardianship, curatorship).\n* Subject currently receiving psychiatric care.\n* Subject deprived of liberty by judicial or administrative decision.","70 Years",{"count":107,"type":20},54,[109],"NA","Polycythemia vera (PV) is a rare haematological disorder characterized by an excessive production of red blood cells, associated with the somatic JAK2 V617F mutation. Clinical manifestations are varied and often include exercise intolerance but the underlying mechanisms remain poorly understood.\n\nPhysical activity is recommended in the management of chronic diseases, but it must be tailored to the physiological profile of the patient. A cardiopulmonary exercise test (CPET) is essential to ensure safety, detect possible contraindications, and assess maximal oxygen uptake (VO₂max), a key indicator of aerobic performance.\n\nThis prospective, experimental, non-randomized study will include patients with PV followed at Lyon Sud University Hospital and for which a CPET is scheduled in their routine clinical follow-up. The primary objective is to compare VO₂max between two groups of patients: moderate (\\\u003C10%) versus marked (≥10%) extent of blood viscosity increase after the completion of the CPET. The main hypothesis is that a significant increase in blood viscosity during exercise (≥10%) is a major limiting factor in oxygen transport and leads to a reduced VO₂max, reflecting impaired exercise tolerance.\n\nSecondary analyses will focus on hemorheological parameters, tissue oxygenation, and cardiorespiratory and metabolic responses. The study aims to better understand the biological and physiological determinants of exercise intolerance in this population.",[26,112],"Polycythemia Vera (PV)",[114,115],"Blood viscosity","polycythemia","2026-01-14",{"date":118,"type":31},"2026-01-15",{"date":120,"type":20},"2026-01",{"date":122,"type":20},"2027-05",{"name":124,"class":38},"Hospices Civils de Lyon",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":39},"100522975","phase-4-cpap-effect-on-the-polycythemia-in-patients-with-obstructive-sleep-apnea-100522975","NCT06089603","CPAP Effect on the Polycythemia in Patients With Obstructive Sleep Apnea","PoliAOS","Inclusion Criteria:\n\n* Subjects from 18 to 80 years old.\n* Diagnosis of polycytemia defined as hematocrit \\> 49% in men and \\> 48% in women. ç\n* Diagnosis of moderate or severe sleep apnea, defined by an apnea-hypoapnea index \\>15. - Patients able to read and understand informed consent and give their signed consent.\n\nExclusion Criteria:\n\n* Smokers or former smokers with pack-year index (IPA\\>30) or chronic obstructive pulmonary disease diagnosed by spirometry (FEV1\u002FFVC post-bronchodilator below the lower limit of normal or z score \\\u003C 1.645).\n* Patients with central sleep apnea or periodic breathing\n* Patients with oxygen saturation \\\u003C92% or pO2\\\u003C 60 mmHg at rest during wakefulness. - Evidence of severe heart failure (LVEF\\\u003C50) or pulmonary hypertension.\n* Patients with primary polyglobulia (polycythemia vera). It will be done prior to the inclusion in the study blood levels of erythropoietin (EPO) and determination of the mutation of the JAK2 V617F gene. Patients with normal or elevated EPO levels (normal limits 2.9- 25.9 mU\u002Fml) and no JAK2 V617F gene mutation\n* Patients with any active neoplasm will be included in the study. - Patients with chronic kidney disease (Glomerular Filtration Rate (GFR) \\\u003C60 mL\u002Fmin\u002F1.73 m2).\n* Patients with any active neoplasia.- Patients with chronic kidney disease (Glomerular Filtration Rate (GFR) \\\u003C60 mL\u002Fmin\u002F1.73 m2).\n* Need for periodic bleeding according to hematology guidelines.\n* Treatment with diuretics.\n* Treatment with antiplatelets or anticoagulants.\n* Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg at the baseline visit.\n* Stroke, transient ischemic attack, acute coronary syndrome or hospitalization due to worsening heart failure, in the previous 30 days .\n* Professional drivers, high-risk profession or respiratory failure (according to criteria of the clinical path of diagnosis and treatment of sleep-related respiratory disorders).\n* High daytime sleepiness (Epworth sleepiness scale \\> 16)\n* Previous treatment with CPAP- Participation in another clinical trial within 30 days prior to randomization.",{"count":133,"type":20},182,[23],"Objectives: To compare the response of polycythemia in terms of hematocrit decrease in patients treated with positive airway pressure (CPAP) versus patients not treated with CPAP.\n\nMethodology: Randomized, parallel-group, nonblinded, controlled clinical trial.\n\nPatients diagnosed with OSA in a respiratory polygraphy (RP) and who meet all the inclusion criteria and none of the exclusion criteria will undergo sleepiness and quality of life questionnaires, anthropometric measurements and blood tests and will be randomized to a CPAP treatment group or control group, maintaining this treatment for 12 months. A visit will be made at 12 weeks ,24 weeks and 52 weeks to check compliance with CPAP in the treatment group and to carry out questionnaires on physical activity and quality of life, anthropometric measurements, blood tests including hemoglobin and hematocrit as well as parameters related to coagulation and platelet function and changes in medication as well as adverse effects.\n\nEfficacy variables: blood count, hemoglobin, haematocrit, erythropoietin, mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), mean platelet volume (MPV), platelets, coagulation, erythrocyte range of distribution (ADE), glucose, creatinine, glomerular filtration rate, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyltransferase (GGT), Total bilirubin, hypoxic burden, Epworth score, EuroQol- 5D questionnaire.",[137,26],"Sleep Apnea, Obstructive","2025-09-11",{"date":140,"type":31},"2025-09-17",{"date":142,"type":31},"2023-11-01",{"date":144,"type":20},"2026-09",{"name":146,"class":38},"Hospital Universitario Ramon y Cajal",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":155,"targetDuration":157,"studyType":48,"phases":4,"briefSummary":158,"conditions":159,"keywords":166,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":39},"100576482","evaluation-of-erythrocytosis-prospective-cohort-study-100576482","NCT06785870","EVAluation of Erythrocytosis PRospEctive Cohort STudy","Evaluation of Erythrocytosis Prospective Cohort Study (EVEREST): Diagnosis, Management and Longitudinal Outcomes in Patients with Elevated Hemoglobin","EVEREST","Inclusion Criteria:\n\n1. Adult patients (\\>=18 years) referred to hematology clinics at London Health Sciences Centre with hemoglobin levels \\>=165 g\u002FL in males or \\>=160 g\u002FL in females.\n2. Patients capable of providing informed consent.\n3. Age \\>= 18 years.\n\nExclusion Criteria:\n\n1. Patients \\\u003C18 years.\n2. Patients without erythrocytosis.\n3. Patients incapable of providing informed consent.",{"count":156,"type":20},1500,"5 Years","The EValuation of ERythrocytosis pRospEctive cohort STudy (EVEREST) is a prospective study designed to shed light on these key questions in the diagnosis, management, and clinical outcomes in patients with elevated hemoglobin (erythrocytosis). This longitudinal, prospective study will generate high quality data that can help inform the optimal approach to diagnosis and management in this patient population.",[160,26,161,162,163,112,164,165],"Erythrocytosis","Polycythemia Secondary","Polycythemia Vera","Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase","Polycythemia; Familial","Polycythemia, Primary",[167,168,160,26,169,170,171,172],"Prospective","Observational Study","Patient Registry","Diagnosis","Management","Outcomes","2025-01-19",{"date":175,"type":31},"2025-01-21",{"date":177,"type":20},"2025-02-01",{"date":179,"type":20},"2030-12-31",{"name":181,"class":38},"Cyrus Hsia",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":39},"100469696","effect-of-phlebotomy-on-heartrate-in-polycythemia-patients-100469696","NCT05396170","Effect of Phlebotomy on Heartrate in Polycythemia Patients","Phlebotomy in Blood Donors and Polycythemia Vera Patients- The Effect on Physiology: An Orienting Case-Cross Over Study","NOSFERATU","Inclusion Criteria:\n\n* Patients with polycythaemia, requiring phlebotomy on a regular basis (at least every 4 months)\n* Subjects aged ≥18 years\n* In possession of a smartphone\n* Life expectancy ≥ 3 months\n\nExclusion Criteria:\n\n* Poor performance\u002Ffunctional status (Eastern Cooperative Oncology Group system ECOG ≥3)\n* Participants with known arrhythmias or other significant cardiological conductivity disorders (Paroxysmal atrial fibrillation is allowed)\n* Hospitalized subjects\n* Subjects with a pacemaker.\n* Subjects with a secondary polyglobulia due to eg smoking or other pulmonary issues.\n* Scheduled oncological treatments or surgery during the study period.",{"count":191,"type":20},10,"Single-centre, observational within-subject design: patients that undergo phlebotomies regularly for polycythemia will be measured continuously by wearables one week before until one week after a phlebotomy, for three phlebotomies.",[26],"2024-11-12",{"date":196,"type":31},"2024-11-13",{"date":198,"type":31},"2022-07-21",{"date":200,"type":20},"2025-01-01",{"name":202,"class":38},"Leiden University Medical Center"]